Online inquiry

IVTScrip™ mRNA-Anti-S, CB-6(Cap 0, 2-Thio-UTP, 30 nt-poly(A))   (CAT#: GTTS-WQ5261MR)

This product GTTS-WQ5261MR is a type of mRNA having 30 nt poly(A) tail and modified with Cap 0 & 2-Thio-UTP. It ecodes the monoclonal antibody that targets S gene. The antibody can be applied in Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection (COVID-19) research.
Specifications
Product type mRNA
Modified bases 2-Thio-UTP
5' Cap Cap 0
Species Homo sapiens
RefSeq YP_009724390.1
Applications Gene therapy research
Format Powder
Quantity 100 µg
Purification oligo-dT affinity purification
Target Gene
Gene ID 43740568
UniProt ID P59594
Download
Download resources about mRNA therapeutics development to boost your research.
CUSTOMER REVIEWS and Q&As

There are currently no Customer reviews or questions for IVTScrip™ mRNA-Anti-S, CB-6(Cap 0, 2-Thio-UTP, 30 nt-poly(A)) (GTTS-WQ5261MR). Click the button above to contact us or submit your feedback about this product.

See other products
CAT Product Name Product Type CDs
GTTS-WQ15094MR IVTScrip™ mRNA-Anti-TNC, ST2146(Cap 1, Pseudo-UTP, 120 nt-poly(A)) mRNA ST2146
GTTS-WQ833MR IVTScrip™ mRNA-Anti-CD276, ABBV-155(Cap 0, N1-Methylpseudo-UTP, 30 nt-poly(A)) mRNA ABBV-155
GTTS-WQ1936MR IVTScrip™ mRNA-Anti-SLITRK6, AGS15C(Cap 1, 5-Methyl-CTP & Pseudo-UTP, 120 nt-poly(A)) mRNA AGS15C
GTTS-WQ12402MR IVTScrip™ mRNA-Anti-CD3E, NI-0401(Cap 1, Pseudo-UTP, 120 nt-poly(A)) mRNA NI-0401
GTTS-WQ14555MR IVTScrip™ mRNA-Anti-CD19, aCD1919(Cap 0, 5-Methyl-CTP & Pseudo-UTP, 120 nt-poly(A)) mRNA aCD1919
GTTS-WQ9640MR IVTScrip™ mRNA-Anti-CD3E&TNFRSF17, JNJ-64007957(Cap 1, N1-Methylpseudo-UTP, 120 nt-poly(A)) mRNA JNJ-64007957
GTTS-WQ1593MR IVTScrip™ mRNA-Anti-MSTN, ACE-083(Cap 0, 5-Methyl-CTP, 30 nt-poly(A)) mRNA ACE-083
GTTS-WQ6765MR IVTScrip™ mRNA-Anti-TACSTD2, DS-1062(Cap 1, Pseudo-UTP, 30 nt-poly(A)) mRNA DS-1062
All products and services are For Research Use Only and CANNOT be used in the treatment or diagnosis of disease.
webinar

EABR Nanoparticles as a Platform Technology for Hybrid mRNA Vaccine Development

November 20th, 2024, 2 PM–3 PM EST

REGISTER NOW